A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)

Inclusion Criteria:

- Diagnosis of T2DM

- On stable diabetes therapy (diet/exercise therapy alone or anti-hyperglycemic agents
[AHA] monotherapy or combination therapy) for at least 6 weeks prior to study
participation OR on metformin (with or without diet/exercise therapy or other AHA
therapy) and is willing to undergo a 10-week metformin wash-off period

- Body Mass Index (BMI) greater than or equal to 18.0 kg/m^2

- Male, postmenopausal female or surgically sterile female

- If a female of reproductive potential, agrees to remain abstinent or to use (or have
their partner use) 2 acceptable combinations of birth control while participating in
the trial and for 14 days after the last use of study drug.

Exclusion Criteria:

- History of type 1 diabetes mellitus or a history of ketoacidosis

- History of other specific types of diabetes (e.g., genetic syndromes, secondary
pancreatic diabetes, diabetes due to endocrine disorders, drug - or chemical-induced,
and post-organ transplant)

- History of nephrotic range proteinuria with hypoalbuminemia and edema

- History of rapidly progressive glomerulonephritis, lupus nephritis, renal or systemic
vasculitis, renal artery stenosis with renovascular hypertension, or ischemic
nephropathy

- History of familial renal glucosuria

- History of renal dialysis or renal transplant or renal disease requiring treatment
with any immunosuppressive agent

- A known hypersensitivity or intolerance to any (sodium-glucose co-transporter 2)
SGLT2 inhibitor

- On a weight-loss program or weight-loss medication or other medication associated
with weight changes and is not weight stable

- Has undergone bariatric surgery within the past 12 months

- Has been treated with rosiglitazone or other SGLT2 inhibitors within 12 weeks of
study participation

- Has active, obstructive uropathy or indwelling urinary catheter

- History of myocardial infarction, unstable angina, arterial revascularization,
stroke, transient ischemic attack, or New York Heart Association (NYHA) functional
class III-IV heart failure within 3 months of study participation

- A history of malignancy ≤5 years prior to study participation, except for adequately
treated basal or squamous cell skin cancer or in situ cervical cancer

- Known history of Human Immunodeficiency Virus (HIV)

- Has blood dyscrasias or any disorders causing hemolysis or unstable red blood cells
or any other clinically significant hematological disorder (such as aplastic anemia,
myeloproliferative or myelodysplastic syndromes, thrombocytopenia)

- A medical history of active liver disease (other than non-alcoholic hepatic
steatosis), including chronic active hepatitis B or C, primary biliary cirrhosis, or
active symptomatic gallbladder disease

- Has any clinically significant malabsorption condition

- If taking thyroid replacement therapy, has not been on a stable dose for at least 6
weeks prior to study participation

- Has been previously randomized in a study with ertugliflozin

- Has participated in other studies involving an investigational drug within 30 days
prior or during study participation

- Has undergone a surgical procedure within 6 weeks prior to or during study
participation

- Has a positive urine pregnancy test

- Is pregnant or breast-feeding, or is planning to conceive during the trial, including
14 days following the last dose of study medication

- Planning to undergo hormonal therapy in preparation to donate eggs during the trial,
including 14 days following the last dose of study medication

- Excessive consumption of alcoholic beverages or binge drinking

- Has donated blood or blood products within 6 weeks of study participation or plans to
donate blood or blood products at any time during the trial